I've switched to Copaxone's generic, Glatopa

You've read it correctly, for the first time since being on Copaxone, I have been switched to a different medication.

Glatopa (Sandoz, a Novartis company, developed in collaboration with Momenta Pharmaceuticals) is the first generic version of Copaxone that has been approved by the U.S.Food and Drug Administration (FDA). Copaxone and Glatopa contain the SAME active ingredient, glatiramer, in the SAME amount and work the SAME way in the body to help manage Multiple Sclerosis (MS). The Glatopa dose will be the same as the Copaxone dose, both 20 mg, is injected daily, in the fatty layer under your skin (subcutaneously). I will also be using a NEW auto-injector device for Glatopa as my Copaxone auto-injector is not compatible with Glatopa syringes.

I am finishing up the last remaining 2-syringe supply of my Copaxone, but I am sure it will be a seamless transition. However, I do think it will be pretty strange/bittersweet to no longer be working with Shared Solutions, who has been my support and network for MS from day one since being on Teva Pharmaceuticals' Copaxone.

Glatopa's GlatopaCare will be the new support network, and I just hope it's as good as SharedSolutions.

I still am still hopeful to eventually switch to the next-generation formulation of Copaxone 40mg, that works longer, and so requires fewer monthly doses. For this to option to happen, I'm waiting on Kaiser to put it on the formulary.